The global clot-busting drugs market is poised for substantial growth, with an estimated market value of around USD 28.8 billion in 2022. Projections indicate a robust Compound Annual Growth Rate (CAGR) of 7.3%, driving the market to soar to a valuation of USD 58.4 billion by the end of 2032.
Thrombolytics, or medications that disintegrate clots, are essential for treating pulmonary emboli, strokes, and heart attacks among other thrombotic illnesses. These medications have the ability to dissolve blood clots and restore blood flow to wounded tissues, which can enhance patient outcomes and reduce the likelihood that severe complications will arise in critical medical conditions.
Because consumers aren’t getting clot busting therapies as desired due to misconceptions and the adverse effects of the treatments, companies are developing new clot busting drugs with less side effects at affordable pricing. This is expected to significantly boost acceptability and usage of clot-busting medications. Growing product releases and approvals are expected to drive further market expansion throughout the projected term.
Preview Next-Level Insights Sample:
https://www.futuremarketinsights.com/reports/sample/rep-gb-15689
Key Takeaways from Market Study
- Anticoagulants are the leading segment as a product, and hold approximately 36.7% market share in 2021, due to the rise in chronic diseases, the development of anticoagulant medicines has become more molecularly and biologically advanced, and emerging nations are increasingly using novel oral anticoagulants.
- Pulmonary Embolism are the leading segment by indication, and held about 31.2% market share in 2021, owing to the increasing number of cancer patients and patients who have a family history of cardiovascular issues.
- Injectable category is the leading segment in route of administration of drugs by holding more than half of the global market share owed to growing need for tools like safety syringes, prefilled syringes, and auto-injectors for the prevention of needle stick injuries.
- Hospital Pharmacy is the leading distribution channel as of 2021, withholding about one third of the global market share by value due to wide range of product availability, convenience and patients’ reliance on hospitals for treatments.
- By region, North America is leading in the global clot busting drugs market with 32.4% of the revenue share on 2021 and is expected to continue to do so with a projected CAGR rate of 8.0% during the forecasted years.
“Rising initiatives to promote health benefits of clot busting drugs, as well as the increasing awareness about the prevention of heart attacks and strokes is set to propel the sales of clot busting drugs devices across the globe,” says an analyst of Future Market Insights.
Market Competition
The market for clot busting drugs is quite competitive due to the presence of numerous local or regional players. The companies are concentrating on implementing different business strategies, such as product launches, drug development, and geographic expansions. For Instance:
- In Dec 2021, Janssen Pharmaceutical received U.S. FDA approval for its oral anticoagulant called XARELTO (rivaroxaban). The drug was approved for 2 indications for pediatric category which includes prophylaxis of DVT or deep vein thrombosis resulting in pulmonary embolism.
- AstraZeneca’s Brilinta (ticagrelor) received FDA approval for its P2Y12 receptor antagonist, an oral, reversible drug that prevents platelet activation, in June 2020 to lower the risk of a stroke or a first heart attack in patients with high-risk of coronary artery disease (CAD).
Customization Available:
https://www.futuremarketinsights.com/customization-available/REP-GB-15689
Key Segments Covered in Clot Busting Drugs Industry Research
By Product:
- Thrombolytic Drugs
- Anti-Platelet Drugs
- Anticoagulants
- Others
By Indication:
- Pulmonary Embolism
- Deep Vein Thrombosis
- Atrial Fibrillation
- Others
By Route of Administration:
- Oral
- Injectable
By Distribution Channel:
- Hospital Pharmacy
- Drug Store
- Online Pharmacy
- Retail Pharmacy
By Region:
- North America
- Latin America
- Europe
- East Asia
- South Asia
- Oceania
- Middle-East and Africa (MEA)
Explore In-Depth Market Insights: Purchase Now to Access:
https://www.futuremarketinsights.com/checkout/15689
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
